GLG News by Dr. Donald Fleming MD, Director of the Cancer Care Center
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Microarrays and the fingerprints of cancer
July 10, 2011
How Bright Promise in Cancer Testing Fell Apart | www.nytimes.com
Genetic testing in regards too cancer cells has been a long time projectMicroaaray techniques using more reliable RNA versus DNA patterns will likely lead the wayProteionomic is is yet a further downstream approach to classifying cancer uniqueness
-
Profitable palliation of none at all?
July 4, 2011
There is a plethora of new treatments for cancer.Universally new cancer treatments are very expensive.There are as many cancer patients being treated for palliative purposes as cure
-
Avastin: a targeted drug without a target?
June 30, 2011
Breast Cancer Patients Plead for Avastin Approval | www.nytimes.com
Targeted cancer therapy is the trend in oncology therapyAvastin is a targeted therapy that has only theory backing up it's mode of actionAvastin has the benefit and drawback of being designated as broadly active yet specific to no cancer!
-
Tarceva gives more proof: One should know the target for Targeted therapy
June 4, 2011
Roche’s Tarceva Stalls Lung Cancer With Gene Mutation in Late-Stage Study | www.bloomberg.com
So called targeted therapy has been a term coined over the last decade in the approach to treating cancer. A recent Roche study demonstrates almost doubling of disease control when one uses a patient population that has a defined target is treated with the drug Tarceva
-
Necessity may be the mother of invention,but the father is profit.
April 16, 2011
Shortage Worsens of Leukemia Drug | online.wsj.com
There is a shortage of many cancer fighting medications, as more and more of the agents used to treat cancer become generic. The problem is both profit and regulation driven.
-
Will provenge fall the way of radioimmunotherapy
November 19, 2010
Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com
Provenge recently approved for HRPC .Provenge was designed for asymptomatic patients with increasing PSAsProvenge involves referral to a specialized center to perform the procedure
-
January 30, 2010
Roche gets EU approval for Herceptin to treat HER2-positive advanced stomach cancer | www.pharmabiz.com
There has been between a 20-30% Her over expression detected on adeno ca of gastric mucosaThe fastest growing esophageal malignancy is GE junction adenoca, which acts and is treated very similar to adeno ca of stomachOther solid tumors are likely to also demonstrate a similar benefit
-
December 16, 2009
BiPar Sciences' BSI-201 phase-3 trial makes progress in metastatic triple-negative breast cancer | www.pharmabiz.com
Recent evidence suggest that PARP is a new enzyme related target for TNBCTNBC sorely needs more effective therapyBe certain, the PARP target is not TNBC specific
-
December 10, 2009
Novartis' Tasigna demonstrates greater efficacy over Glivec in chronic myeloid leukaemia | www.pharmabiz.com
Gleevec has revolutionized outcome/ therapy in CMLRecent phase III demonstrates better tolerance of Tasigna over GleevecCML outcome is reflected in MR and Tasigna seems to do it better
-
Roche's Avastin declined by European "bean counters" for brain tumor
November 23, 2009
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer | www.pipelinereview.com
Avastin utilized successfully in US for primary brain tumors, including the very aggressive GBMHealth care, including cancer, will be all about rationingRoche and other pharma companys better get ready for a rough future
-
November 14, 2009
US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com
Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients
-
Triple negative Breast Cancer Strategies
October 14, 2009
MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com
Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as for non small cell lung cancer
-
Farletuzumab (F) helps the ovarian cancer patients that do well, do well?
September 25, 2009
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com
F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we have a problem with
-
Herceptin for Her2 + gastric cancer, If you can find one
September 25, 2009
Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com
Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer
-
REGORAFENIB joins a crowd of TKI's for RCC
September 25, 2009
Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com
RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved
-
Pay for performance Medicare "reform"
May 4, 2009
Medicare System Overhaul Proposed by Two Senators | www.nytimes.com
Medicare will reward based on outcome Medicare will pay for chronic illness acre based on outcome results Be careful about heading towards cancer care rationing
-
February 27, 2009
Intas Biopharma to market Pemetrexed in India soon | www.pharmabiz.com
Alimta has been approved as upfront treatemnt of NSCLCA with platinum Alimta approved US as single agent salvage treatment NSCLCa Market share IN US hsa been crowded out by other platinum combinations
-
tarceva adds to avastin but avastin doesn't add to tarceva?
February 17, 2009
OSI, Genentech Say Cancer Drug’s Benefits Ends Trial (Update2) | www.bloomberg.com
Beta lung demonstrated no benefit of adding avastin to tarceva as second line advanced lung cancer therapy Atals trial demonstrates adding tarceva to avastin after chemo in advanced lung cancer does benefit
-
More may or may not be better in colorectal cancer
February 6, 2009
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | nejm.highwire.org
Recent trial such as PACE and CAIRO imply combo biologics are not helpful Is it likely this will hold true in future situations?
-
Plitidepsin ( Aplidin) helps in PTCL patients
January 19, 2009
PharmaMar announces the extension of Phase II trial with Aplidin(R) in Peripheral T-Cell Lymphoma after the excellent preliminary results | www.pipelinereview.com
New drug plitidepsin has anti tumor effects in PTCL patients PTCL is a relatively rare NHL form of NHL Plitidepsin has much more financial potential outside of NHL
- Subscribe to Updates
-
Leading institutions connect with Donald Fleming through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.